SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head...

Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week

Equity

Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking. 

Zymeworks Issues Updated 2026 Financial Guidance

(RTTNews) - Zymeworks (ZYME) said the company now expects total revenue for 2026 to be between $278 million and $292 million and 2026 adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions. The company announced the updated fi...

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?

SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.


TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$GILD" data-symbol-id="GILD" href="https://stocktwits.com/symbol/GILD" target="_blank">Gilead Sciences</a> agreed on Thursday to buy Shanghai-based PepStar Therapeutics’ experimental oral drug program for inflammatory diseases.&nbsp;</li><li>Roche gained exclusive global rights to Zymeworks’ ZW209 in a deal worth up to $813 million plus royalties.</li><li>Roche and Hansoh Pharma also expanded their antibody-drug conjugate partnership in a deal that could exceed $15 billion in total value.</li></ul><p>Large drugmakers continued to favor targeted asset purchases and licensing deals for early-stage, differentiated candidates rather than full company acquisitions this week, implying a shift from earlier this year, when full-scale acquisitions dominated the sector.</p><p>Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking, as companies sought to fill specific pipeline gaps. The sole exception was Merck KGaA’s roughly $1.3 billion purchase of Silence Therapeutics.</p><h2 class="st-heading-2">Gilead Acquires Oral Drug Program For $1.275B</h2><p>Gilead Sciences (GILD) agreed on Thursday to buy Shanghai-based PepStar Therapeutics’ experimental oral drug program for inflammatory diseases, including its lead candidate HCXT-2001, for $1.275 billion in cash.</p><p>Gilead sees potential to develop the early-stage asset alone or in combination with its own oral drug emvistegrast as an all-oral approach for inflammatory bowel disease. The deal is expected to close in the fourth quarter and gives Gilead worldwide rights. The deal comes as part of Gilead’s efforts to expand its inflammation portfolio beyond its core HIV business and follows a mid-October collaboration deal with Vir Biotechnology.</p><h2 class="st-heading-2">Roche Licenses Zymeworks' Drug For Lung Cancer</h2><p>U.S.-listed shares of Switzerland-based Roche (RHHBY) gained exclusive global rights to Zymeworks’ (ZYME) ZW209 in a deal worth up to $813 million plus royalties. Zymeworks will receive $55 million upfront and $40 million upon initiation of a Phase 1b trial, with eligibility for up to $718 million in additional development, commercial, and sales milestones, plus tiered high-single-digit to mid-teen royalties.</p><p>Zymeworks will run the Phase 1a monotherapy study with Roche funding, after which Roche takes over global development and commercialization. The candidate targets DLL3, a protein commonly expressed on small-cell lung cancer cells.</p><h2 class="st-heading-2">Roche Expands ADC Collaboration With Hansoh</h2><p>Roche and China-based pharmaceutical company Hansoh Pharma also expanded their antibody-drug conjugate (ADC) partnership in a deal that could exceed $15 billion in total value. Hansoh will receive $400 million upfront and $110 million on the first anniversary, plus eligibility for more than $15 billion in development, regulatory, and commercialization milestones, along with royalties.</p><p>The collaboration covers two preclinical Hansoh ADC programs and multiple additional programs against Roche-selected targets using Hansoh’s platform. Hansoh will lead development through global Phase 1a trials. Roche then takes over worldwide development outside Greater China, where Hansoh retains rights. The agreement builds on a prior single-asset ADC partnership and underscores Roche’s continued push into next-generation ADCs across multiple cancer types.</p><h2 class="st-heading-2">Merck KGaA To Acquire Silence Therapeutics For $1.3B</h2><p>Merck KGaA on Monday agreed to acquire Silence Therapeutics (SLN) in an all-cash deal with an equity value of approximately $1.3 billion. The German drugmaker will pay $20 per American Depositary Share, representing a roughly 130% premium to the stock’s close before the deal announcement.</p><p>The main prize is divesiran, a late-stage-ready therapy for a rare blood cancer. The transaction is expected to close in the first quarter of 2027 and adds both a late-stage rare-disease asset and RNA technology to Merck’s pipeline.</p><p>On Stocktwits, retail sentiment around GILD was 'neutral' at the time of writing, while sentiment around RHHBY, ZYME, and SLN was 'bullish' or 'extremely bullish.'</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/space-x-s-80-000-cell-site-push-a-win-for-asts-ericsson-nokia-next-nav-among-others-says-roth-capital/cZxywyDRBUI">SpaceX’s 80,000 Cell Site Push A Win For ASTS, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;</p>

Digital background depicting innovative technologies in medicine systems, neural interfaces and research genetic and biology. Source: Getty Images

Gilead Sciences, Inc.

Roche Holdings AG ADR

Zymeworks Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZYME Zymeworks Inc

Fundamentals

Latest ZYME News